The effect of bone marrow-derived mesenchymal stem cell co-transplantation with hematopoietic stem cells on liver fibrosis alleviation and survival in patients with class III β-thalassemia major

Abstract

Background Hepatic fibrosis is a common complication in transfusion-dependent thalassemia patients. Data on the co-transplantation of mesenchymal stem cells (MSCs) with hematopoietic stem cells (HSCs) in beta-thalassemia major patients are scarce. Therefore, we aimed to evaluate the effect of co-transplantation of bone marrow-derived MSC with HSCs on the liver fibrosis alleviation and transplant outcomes in class III beta-thalassemia major. Methods Between April 1998 and January 2017, a total of 224 consecutive patients with class III beta-thalassemia major underwent allogeneic HSCT in the Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran. To assess liver fibrotic changes after transplantation, 47 patients participated in the MSC plus HSC group and 30 patients in the HSC only group at the end of the follow-up period. All patients underwent laboratory tests, especially serum ferritin and liver function testing, hepatic T2* MRI, liver biopsy, and FibroScan before and 2 years after transplantation. Kaplan-Meier curves were derived to determine survival and were compared using the log-rank test. Repeated-measure, mixed-effect linear regression models were used to examine the changes in liver fibrosis over time. Results The 10-year OS rate was 71.84% in the mesenchymal group and 61.89% in the non-mesenchymal group (P value = 0.294), while the 10-year TFS rate was 63.64% in the mesenchymal group and 52.78% in the non-mesenchymal group (P value = 0.285). No significant difference was observed in the 10-year NRM, rejection rate, ANC engraftment, platelet engraftment, acute GvHD, and chronic GvHD between the two groups. In addition, the results of repeated-measure, mixed-effect linear regression models showed that none of the variables determining hepatic fibrosis had a significant difference between patients receiving MSCs and patients who did not receive MSCs. Conclusions Based on the results of this study, a single infusion of MSCs at the time of HSCT to patients with class III beta-thalassemia major could not significantly improve the liver fibrosis alleviation and transplantation outcomes, including OS, TFS, TRM, rejection rate, ANC engraftment, platelet engraftment, acute GvHD, and chronic GvHD.

Targeting Reprogrammed Cancer-Associated Fibroblasts with Engineered Mesenchymal Stem Cell Extracellular Vesicles for Pancreatic Cancer Treatment

“…Various studies have demonstrated that external BMSC administration exerts effective therapeutic and protective effects on fibrotic diseases [ 35 , 36 ]. Pancreatic cancer is characterized by abundant CAFs in the stroma.…”

Immune response: the Achilles’ heel of the stem cell-based regenerative therapies

“…This synergic crosstalk involves both direct cell-to-cell interaction and stemness signals from MSCs to HSCs and from HSCs to MSCs (Figure 3). This intrinsic relationship has been explored through the analysis of the combined effect of HSC transplantation (HSCT) with MSC [90,91] or by their combined effect in several studies to evaluate its therapeutic potential to regenerate damaged tissues [87,92,93].…”

Stem cells for treatment of liver fibrosis/cirrhosis: clinical progress and therapeutic potential

“…But the most recent research showed that MSC co-transplantation with HSC or Treg is feasible, but this approach couldn’t significantly improve liver fibrosis than HSC infusion only. Robust evidence that the MSCs used to support the donor's HSCs is of recipient origin [ 13 ]. In addition, intravenous MSCs have a short lifespan and cannot migrate out of the lungs [ 14 ].…”